Loading stock data…
MiMedx Group, Inc (MDXG)
$4.67+0.10 (+2.19%)
Market ClosedLast close Sep 8
MiMedx Group, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MiMedx Group, Inc. in the Healthcare sector is trading at $4.67 with a market capitalization of $622M. Wall Street consensus targets $7.40 (5 analysts), implying a +58.5% move over the next 12 months. The stock is currently 41% below its 52-week high of $7.97, remaining 0.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +58.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $64.36M↑ | $58.99M↓ | $118.09M↑ | $113.72M↑ | $98.61M |
| Gross Profit | $44.38M↑ | $41.62M↓ | $99.04M↑ | $95.01M↑ | $79.92M |
| Operating Income | -$18.47M↓ | -$16.05M↓ | $21.08M↓ | $22.19M↑ | $12.37M |
| Net Income | -$14.84M↓ | -$10.86M↓ | $15.19M↓ | $16.75M↑ | $9.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PU...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$622.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
106.75
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.89%
Volume
Today's trading volume
1.06M
Recent News
MiMedx (MDXG) Q2 2026 Earnings Call Transcript
Surgical revenue grew 15% as wound care stabilized ahead of $350M Sanara deal.
MiMedx Group, Inc. Q2 2026 Earnings Call Summary
Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call
MiMedx Group Inc (MDXG) (Q2 2026) Earnings Call Highlights: Surgical Growth and Transformative ...
MiMedx reports strong surgical momentum and a transformational acquisition, while navigating a challenging wound care market with early signs of stabilization.
MiMedx Group Q2 Earnings Call Highlights
MiMedx Group (NASDAQ:MDXG) said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx’s second-quarter results, which showed sequential improvement in its wound-care busines
MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut
MiMedx Group is back in focus as analysts revisit their price targets, with several firms trimming expectations by roughly US$1 to US$5 while the modeled fair value sits at US$6.50. Those moves line up with research that balances optimism about MiMedx Group’s business against concerns around execution and how the stock is currently priced. Read on to see what these shifts could mean for you and how to track the evolving analyst narrative from here. Stay updated as the Fair Value for MiMedx...